NCT01316263 2017-03-09A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal TumorsEli Lilly and CompanyPhase 2 Terminated21 enrolled 24 charts